title: Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
authors.forename: S
authors.initials: S
authors.lastname: Mercadante
authors.forename: G
authors.initials: G
authors.lastname: Avola
authors.forename: S
authors.initials: S
authors.lastname: Maddaloni
authors.forename: G
authors.initials: G
authors.lastname: Salamone
authors.forename: F
authors.initials: F
authors.lastname: Aragona
authors.forename: V
authors.initials: V
authors.lastname: Rodolico
mesh_terms: D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007415:Intestinal Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery*; D007422:Intestines / Q000187:drug effects / Q000473:pathology; D009369:Neoplasms / Q000150:complications / Q000601:surgery; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D011300:Preoperative Care
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide